CAS has migrated to this web app on 5/23/21. If you have an active membership on 5/23/21, log in with your email and password. Otherwise, please create a new account.
of the Chinese Antibody Society
Register today to reserve your seat
CAS Members can sign in to view recordings
AntibodyPlus: next generation antibody-based biologics
In the midst of the rapid development of novel antibody therapies and the “new normal” of the pandemic, the Chinese Antibody Society (CAS) will hold the 2022 Annual Conference in Boston on October 30, 2022 (Sunday). This will be the first in-person event of the Chinese Antibody Society since the pandemic started. The topic of the CAS 2022 Annual Conference is: “AntibodyPlus: next generation antibody-based biologics.”
Emerging targets for immuno-oncology
The next 100 antibodies to be approved by FDA: emerging antibody modalities and beyond
In our two half-day events, speakers from both industry and academia will share their insights in diverse topics of antibody-based therapeutics and discuss the new trend AntibodyPlusTM integration. This event is a perfect opportunity for the attendees to stay up to date on the most recent progress and challenges in antibody-based drug development.
New Horizon of Antibody Drug Conjugate (ADC)
FREE Registration is now open for mAbTalks series in 2021 - “New Horizon of Antibody-Drug Conjugate (ADC)” virtual symposium. The symposium will be held online on May 23, 2021. In this half-day event, speakers from both industry and academia will share their insights in diverse topics of ADC-based therapeutics, including discovery & new techniques, clinical development.
Revisit the Perspectives of Bispecific Antibodies under the COVID-19 Pandemic
Bispecific and multispecific antibody-based therapies are at the cutting-edge of therapeutic biologics development, and provide new opportunities to address unmet medical needs. In our one-day symposium, eight speakers from both industry and academia will share insights on all aspects of bispecific antibody-based therapeutic development, including novel targets and molecular formats, development of the lead candidate from discovery to clinics, CMC challenges and strategies, regulatory considerations, patent protection strategies, and COVID-19 related therapeutics.